Crestor pulls through again for Shionogi
This article was originally published in Scrip
Executive Summary
Royalties from global licensee AstraZeneca's sales of Crestor (rosuvastatin) continued to surge for Shionogi in the nine months to 31 December, providing a welcome boost to the Japanese firm's top line.